Company intelligence / Profile preview

麗寶生醫

Tamsui District, New Taipei City, Taiwanlibobio.com ↗

Ownership: Private
Development stage: Commercial

Overview

麗寶生醫 has established itself as a leader in precision medicine in Taiwan with over two decades of experience. It operates CAP-accredited laboratories, collaborates with more than twenty hospitals, and offers a range of services from next-generation sequencing-based genetic tests to advanced stem/immune cell therapies. The company was the first globally to identify certain local tumor resistance gene mutations. Its clinical-grade labs have ISO15189 certification. In China, it operates third-party NGS labs serving major hospitals.

Therapeutic areas: OncologyInfectious DiseasesRare DiseasesOther
Modalities: Cell therapyMolecular diagnostics/Genetic testingSmall molecule
Industry: Biotech

Partnerships

Collaborates with over twenty hospitals across Taiwan for clinical service delivery and product validation.

Beyond the preview

Go deeper on 麗寶生醫.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 麗寶生醫.

Explore the full profile